Those receiving IL-6 inhibitors or JAK inhibitors had a trend toward higher risk, but this did not reach statistical significance (Supplementary Table 3).
← all excerpts
Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study.
1
—
—